Louis Lacombe

Quebec, QC, Canada

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 140 publications

Cohort profile: BioCaPPE (Biomarkers of Prostate Cancer/Prevention and Environment) - a Canadian multicentre prospective study of lifestyle and candidate biomarkers in relation to prostate cancer risk.

Cohort profile: BioCaPPE (Biomarkers of Prostate Cancer/Prevention and Environment) - a Canadian multicentre prospective study of lifestyle and candidate biomarkers in relation to prostate cancer risk.

Journal: BMJ open
Published: May 28, 2026

Trajectory timelines and treatment efficacy of 177Lu-PSMA-617 radioligand therapy for metastatic castration-resistant prostate cancer Real-world data from 50 consecutive cases treated in a single Canadian center.

Trajectory timelines and treatment efficacy of 177Lu-PSMA-617 radioligand therapy for metastatic castration-resistant prostate cancer Real-world data from 50 consecutive cases treated in a single Canadian center.

Journal: Canadian Urological Association journal = Journal de l'Association des urologues du Canada
Published: February 17, 2026

Androgenic effects of 11-oxyandrogens in castration-resistant prostate cancer.

Androgenic effects of 11-oxyandrogens in castration-resistant prostate cancer.

Journal: BMC cancer
Published: June 17, 2025

Noncanonical functions of UGT2B17 promote castration-resistant prostate cancer progression.

Noncanonical functions of UGT2B17 promote castration-resistant prostate cancer progression.

Journal: The Journal of clinical investigation
Published: June 10, 2025

Prognostic Significance of the Cytoplasmic Expression of UDP-glucuronosyltransferase 2B17 in Localized Prostate Cancer: Insights from the Canadian Prostate Cancer Biomarker Network and PROCURE Multi-institutional Cohorts.

Prognostic Significance of the Cytoplasmic Expression of UDP-glucuronosyltransferase 2B17 in Localized Prostate Cancer: Insights from the Canadian Prostate Cancer Biomarker Network and PROCURE Multi-institutional Cohorts.

Journal: European urology oncology
Published: May 16, 2025

First-line Pembrolizumab Plus Lenvatinib for Advanced Non-clear-cell Renal Cell Carcinoma: Updated Results from the Phase 2 KEYNOTE-B61 Trial.

First-line Pembrolizumab Plus Lenvatinib for Advanced Non-clear-cell Renal Cell Carcinoma: Updated Results from the Phase 2 KEYNOTE-B61 Trial.

Journal: European urology
Published: February 18, 2025

Reply by Authors.

Reply by Authors.

Journal: The Journal of urology
Published: December 17, 2024

High 11-Ketotestosterone Linked to Shorter Time to Castration Resistance in Recurrent Nonmetastatic Prostate Cancer.

High 11-Ketotestosterone Linked to Shorter Time to Castration Resistance in Recurrent Nonmetastatic Prostate Cancer.

Journal: The Journal of urology
Published: November 15, 2024

Long term evaluation of optimized Gleason grading in a large cohort of men with prostate cancer in Canada.

Long term evaluation of optimized Gleason grading in a large cohort of men with prostate cancer in Canada.

Journal: Human pathology
Published: March 02, 2024

Regulatory and memory T lymphocytes infiltrating prostate tumors predict long term clinical outcomes.

Regulatory and memory T lymphocytes infiltrating prostate tumors predict long term clinical outcomes.

Journal: Frontiers in immunology
Published: January 18, 2024

Salvage therapy for BCG failure with intravesical sequential gemcitabine and docetaxel in patients with recurrent NMIBC.

Salvage therapy for BCG failure with intravesical sequential gemcitabine and docetaxel in patients with recurrent NMIBC.

Journal: Canadian Urological Association journal = Journal de l'Association des urologues du Canada
Published: November 06, 2023

The Germline and Somatic Origins of Prostate Cancer Heterogeneity.

The Germline and Somatic Origins of Prostate Cancer Heterogeneity.

Journal: Cancer discovery
Published: August 03, 2023
Showing 1-12 of 140

Last Updated: 09/26/2026